A dosage trial of Verona Pharma’s inhaled mixed phosphodiesterase (PDE) 3/4 inhibitor RPL554 for the treatment of mild asthma has demonstrated positive bronchodilation without any significant adverse effects at dosages two and four times higher than had been tested in a previous safety study. Verona is looking to license the drug or to find a partner for continued development. Read the company’s press release.
